MyHorryNews

D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002

D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has ...
Targeted Oncology

Phase 3 Trial of Calderasib Combo Launched in Advanced KRAS G12C-Mutant NSCLC

The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...
The Tufts Daily

DIRAS3: A new target for KRAS-driven cancers

Responsible for nearly 10 million deaths worldwide in 2020, cancer consistently ranks among the leading causes of death each year. Brought on by genetic mutations and external risk factors, cancer is ...
Seeking Alpha

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

GRAND CAYMAN, Cayman Islands, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference ...
FierceBiotech

AACR: Verastem, Quanta and Frontier demonstrate KRAS inhibitors' potential in preclinical data

Verastem Oncology, Frontier Medicines, Quanta Therapeutics and more shared preclinical updates at the American Association for Cancer Research’s (AACR's) annual meeting in San Diego in early April, ...